These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein. Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026 [TBL] [Abstract][Full Text] [Related]
6. Timing of the hepatic arterial phase at Gd-EOB-DTPA-enhanced hepatic dynamic MRI: comparison of the test-injection and the fixed-time delay method. Nakamura S; Nakaura T; Kidoh M; Utsunomiya D; Doi Y; Harada K; Uemura S; Yamashita Y J Magn Reson Imaging; 2013 Sep; 38(3):548-54. PubMed ID: 23744782 [TBL] [Abstract][Full Text] [Related]
7. Double hepatic arterial phase MRI of the liver with switching of reversed centric and centric K-space reordering. Kanematsu M; Goshima S; Kondo H; Yokoyama R; Kajita K; Hoshi H; Onozuka M; Nozaki A; Hirano M; Shiratori Y; Moriyama N AJR Am J Roentgenol; 2006 Aug; 187(2):464-72. PubMed ID: 16861552 [TBL] [Abstract][Full Text] [Related]
8. Gadolinium-enhanced MR imaging of the liver: optimizing imaging delay for hepatic arterial and portal venous phases--a prospective randomized study in patients with chronic liver damage. Kanematsu M; Semelka RC; Matsuo M; Kondo H; Enya M; Goshima S; Moriyama N; Hoshi H Radiology; 2002 Nov; 225(2):407-15. PubMed ID: 12409573 [TBL] [Abstract][Full Text] [Related]
9. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial. McClellan TR; Motosugi U; Middleton MS; Allen BC; Jaffe TA; Miller CM; Reeder SB; Sirlin CB; Bashir MR Radiology; 2017 Feb; 282(2):361-368. PubMed ID: 27509544 [TBL] [Abstract][Full Text] [Related]
10. Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough? Corwin MT; Lamba R; McGahan JP J Magn Reson Imaging; 2013 Apr; 37(4):993-8. PubMed ID: 23001618 [TBL] [Abstract][Full Text] [Related]
11. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. Frericks BB; Loddenkemper C; Huppertz A; Valdeig S; Stroux A; Seja M; Wolf KJ; Albrecht T AJR Am J Roentgenol; 2009 Oct; 193(4):1053-60. PubMed ID: 19770329 [TBL] [Abstract][Full Text] [Related]
12. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Davenport MS; Caoili EM; Kaza RK; Hussain HK Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733 [TBL] [Abstract][Full Text] [Related]
13. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. Choi JY; Kim MJ; Park YN; Lee JM; Yoo SK; Rha SY; Seok JY AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086 [TBL] [Abstract][Full Text] [Related]
14. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092 [TBL] [Abstract][Full Text] [Related]
19. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy? Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997 [TBL] [Abstract][Full Text] [Related]
20. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver. Chung SH; Kim MJ; Choi JY; Hong HS J Magn Reson Imaging; 2010 Feb; 31(2):365-72. PubMed ID: 20099350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]